Sector Glance: Biotech Stocks Rise - Forbes.com

Sector Glance: Biotech Stocks Rise - Forbes.com:

"Porges also said the regulatory environment, despite some high profile safety driven labeling changes, is relatively benign for biotech companies.

'Biotech companies tend to be developing and marketing treatments for serious, often life-threatening illness. Such treatments are not subject to the same risks of rare serious side effects in broad usage,' he wrote."

I'm not sure I agree with that, but we'll see.